Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers watch and learn: no new treatment for rare sarcoma

NCT ID NCT03099681

Knowledge-focused Sponsor: Italian Sarcoma Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing 100 people with epithelioid sarcoma, a rare cancer. Researchers will track what treatments patients receive and how they respond. The goal is to better understand the disease and current care, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2017

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient affected by epithelioid sarcoma according to 2014 WHO classification

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen 2. Signed informed consent 3. Adequate patient compliance to treatment or follow up 4. No age limit Exclusion criteria 1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. Impossibility to ensure adequate compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelioid sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epithelioid sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelioid sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Paolo Giaccone

    RECRUITING

    Palermo, PA, 90127, Italy

  • Campus Biomedico

    RECRUITING

    Roma, Italy

  • Fondazione IRCCS INT Milano

    RECRUITING

    Milan, Italy

  • Fondazione del Piemonte per l'Oncologia IRCC Candiolo

    RECRUITING

    Candiolo, Torino, 10060, Italy

  • Irccs Istituto Oncologico Veneto (Iov)

    RECRUITING

    Padova, Italy

  • Istituti Fisioterapici Ospitalieri di Roma

    RECRUITING

    Roma, Italy

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, MI, 20089, Italy

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, MI, 20141, Italy

  • Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors

    RECRUITING

    Bologna, 40136, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST

    RECRUITING

    Meldola, FC, Italy

  • Ospedale Misericordia e Dolce Ist. Toscano Tumori, Az. USL4

    RECRUITING

    Prato, 59100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.